Loading...
Loading...
ARAV| Name | Value |
|---|---|
| Revenues | 2.8M |
| Cost of Revenue | 8.7M |
| Gross Profit | -6.0M |
| Operating Expense | 11.7M |
| Operating I/L | -8.9M |
| Other Income/Expense | 29.9M |
| Interest Income | 0.2M |
| Pretax | 21.2M |
| Income Tax Expense | -29.4M |
| Net Income/Loss | 21.2M |
Aravive, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for life-threatening diseases, such as cancer and fibrosis. The company's lead product candidate, batiraxcept, is in Phase III clinical trial for platinum-resistant recurrent ovarian cancer and in Phase Ib/II clinical trial for clear cell renal cell carcinoma and pancreatic adenocarcinoma. Additionally, Aravive is developing AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. The company has strategic collaborations and license agreements to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis, as well as products containing batiraxcept for the treatment of oncological diseases in specific regions.
